Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan

19-Oct-2017 Intellasia | BusinessWire | 10:45 PM Print This Post
  • Vivian Wang and Takashi Hayashi will strengthen Median’s growth in
    Asia.
  • With these appointments, and the recently announced opening of its
    subsidiary in Hong Kong, Median intends to significantly invest in and
    grow its business in the Asian market.

SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News:

Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®
today announces the appointment of Vivian Wang as General Manager, China
and the appointment of Takashi Hayashi as Managing Director, Japan.

As General Manager of China, Ms. Wang is responsible for scaling
Median’s operations and commercial teams. As the General Manager, she
will ensure the execution of the strategic plan across Greater China and
the delivery of key company and customer milestones.

Vivian previously worked at Philips Healthcare where she spent a
significant part of her career as the Business Leader for healthcare
informatics, in which role she developed short-term and long-term
business strategy, localized solution portfolio, new product
introduction, distributor channel, clinical application and marketing
communication strategy for the Greater China market. Vivian had direct
P&L responsibility and used her experience to understand the software
and healthcare markets in China, the Ministry of Health and the
regulatory pathways for new product development as well as building a
strong network of Key Opinion Leaders.

Vivian graduated from the Guanghua School of Management, Peking
University.

“I am so pleased to join Median Technologies as one of the leadership
members. As a healthcare marketer, I recognize Median’s excellent
corporate culture, comprehensive edge-cutting solutions, which I believe
will impact our doctors’ ability to provide precise therapy and improve
the patient experience. The China market provides a growing opportunity
for our business, and I look forward to further developing and extending
Median’s global network,”
said Ms. Wang.

As Managing Director, Japan, Takashi Hayashi is responsible for the
development and scaling of Median’s business in Japan.

Mr. Hayashi has nearly 30 years of professional experience in the
pharmaceutical industry, where he was at a Contract Research
Organization (CRO). He has over 13 years of research and business
experiences in clinical trials related to pharma/biotech products and
health/functional foods.

Previously, Takashi served as Director, Business Development and Key
Accounts Asia-Pacific and Japan Country Manager, at BioTelemetry
Research, the Research Division of BioTelemetry, Inc. Prior to
BioTelemetry Research, he also held senior management positions as the
Operating Officer and Director for Sales, Marketing & Business
Development at Ina Research Inc., a leading Japanese CRO, as well as
serving as the President & Chief Operating Officer at its Philippine
subsidiary, INA RESEARCH PHILIPPINES, INC.

Takashi holds a Bachelor of Science in Life Science from the Tokyo
College of Medico-Pharmaco Technology (Japan) and Pacific Western
University (off-campus, Hawaii). He is also a part-time researcher at
the Department of Pharmacology, School of Medicine in Toho University,
Japan.

“As a professional business developer and innovator, I am very
honored to be joining the Median organization.
I am also happy
and excited to deliver outstanding Median services, expertise and
technologies to pharmaceutical and healthcare companies in Japan to help
with the development of a healthier world,”
said Mr. Hayashi.

The Asian market represents a significant development opportunity
for Median’s clinical trials and patient care business lines. Both
Vivian’s and Takashi’s in-depth knowledge of the China and Japan markets
will be instrumental for strengthening our position in this region. We
are very excited to welcome them to our company,
” said Jeanne
Hecht, Chief Operating Officer of Median Technologies. “Along with
these two major appointments, we recently announced the opening of our
new subsidiary in Hong Kong, which will allow the company to directly
access the Asian market. We are also leveraging our Chinese Investor,
FURUI, to build and further develop KOL networks for our patient care
business line,”
she added.

About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We leverage the power of Imaging Phenomics to provide insights
into novel therapies and treatment strategies. Our unique solutions, LMS
for lesion management and iBiopsy® for imaging phenotyping, together
with our global team of experts, are advancing the development of new
drugs and diagnostic tools to monitor disease and assess response to
therapy. Median Technologies supports biopharmaceutical sponsors and
healthcare professionals around the world to quickly and precisely bring
new treatments to patients in need, with an eye on reducing overall care
costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary
in Boston, Median has received the label “Innovative company” by the BPI
and is listed on Euronext Growth market (ISIN: FR0011049824, ticker:
ALMDT). The company is eligible for the PEA-PME SME equity savings plan
setup and has received the label Pass French Tech Promotion 2016-2017.
Median Technologies has been awarded the 2017 Tech 40 Label and has
joined the EnterNext Tech 40 Index. Median is a member of the Bpifrance
Excellence Network. For more information: www.mediantechnologies.com

Contacts

Median Technologies
Fredrik Brag, CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com
or
Press
– ALIZE RP

Caroline Carmagnol / Wendy Rigal
+ 33 1 44 54
36 66
median@alizerp.com
or
Investors
– ACTIFIN

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

 


Category: BusinessWire, PRAsia

Print This Post